Michel Bouvier "Michel Bouvier is a professor of Biochemistry and Molecular Medicine and the CEO of the Institute for Research in Immunology and Cancer ( IRIC ) at the Université de Montréal. In 1989, he returned to Montréal as a professor of biochemistry and a scholar of the Medical Research Since 2001, he holds the Canada Research Chair in Signal Transduction and Molecular Pharmacology. He has supervised the research work of 75 graduate students and 40 post-doctoral fellows.

Michel Bouvier Michel Bouvier is a professor of Biochemistry and Molecular Medicine and the CEO of the Institute for Research in Immunology and Cancer ( IRIC ) at the Université de Montréal. In 1989, he returned to Montréal as a professor of biochemistry and a scholar of the Medical Research Since 2001, he holds the Canada Research Chair in Signal Transduction and Molecular Pharmacology. He has supervised the research work of 75 graduate students and 40 post-doctoral fellows.

Michel Bouvier Michel Bouvier is a professor of Biochemistry and Molecular Medicine and the CEO of the Institute for Research in Immunology and Cancer ( IRIC ) at the Université de Montréal. In 1989, he returned to Montréal as a professor of biochemistry and a scholar of the Medical Research Since 2001, he holds the Canada Research Chair in Signal Transduction and Molecular Pharmacology. He has supervised the research work of 75 graduate students and 40 post-doctoral fellows.

for Cancer Research. He is a Professor in the Departments of Medicine, Immunology and Medical Biophysics at the University Institute in Toronto and with Patrice Dubreuil at INSERM, France. Rottapel’s research interests lies in the elucidation of signal transduction pathways in cancer, immune Robert Rottapel on the web The Rottapel Lab Ontario Institute for Cancer Research University of Toronto

< GPCR News < GPCRs in Oncology and Immunology A2aR on lung adenocarcinoma cells: A novel target for cancer therapy via recruiting and regulating tumor-associated macrophages Published date May 28, 2023 Meetings, and Webinars Reviews, GPCRs, and more GPCR Binders, Drugs, and more Methods & Updates in GPCR Research GPCRs in Neuroscience GPCRs in Cardiology, Endocrinology, and Taste GPCRs in Oncology and Immunology

< GPCR News < GPCRs in Oncology and Immunology From odor to oncology: non-canonical odorant receptors in cancer Published date December 12, 2023 Abstract "Odorant receptors, traditionally associated with types, suggesting their contributions to cancer progression. Meetings, and Webinars Reviews, GPCRs, and more GPCR Binders, Drugs, and more Methods & Updates in GPCR Research GPCRs in Neuroscience GPCRs in Cardiology, Endocrinology, and Taste GPCRs in Oncology and Immunology

antagonists in inflammatory diseases and cancers Published date March 15, 2023 Abstract " C-X-C motif is G protein-coupled receptor (GPCR) and plays important roles in various inflammatory diseases and cancers , including chronic obstructive pulmonary disease (COPD), atherosclerosis, asthma, and pancreatic cancer structure-activity relationships and clinical significance of CXCR2 antagonists in inflammatory diseases and cancers Authors Yishi Xie , Wenbin Kuang , Dawei Wang , Kai Yuan , Peng Yang Tags CXCR2 , CXCR2 antagonist , Cancer

< GPCR News < GPCRs in Oncology and Immunology Chemokine Physiology in Cancer Published date November In cancer, chemokines play paradoxical roles in both the directed emigration of metastatic, receptor-expressing cancer cells out of the tumor as well as immigration of tumor infiltrating immune cells that culminate Facets of chemokine physiology across discrete cancer immune phenotypes are contrasted to existing chemokine-centered therapies in cancer.

Published date November 15, 2023 Abstract "Epstein-Barr virus (EBV) is the oncogenic driver of multiple cancers However, the underlying mechanism of virus-cancer immunological interaction during disease pathogenesis as immune-inflamed, -deficient, and -desert phenotypes, in association with different setpoints of cancer-immunity expression of chemokine receptor-1 (CCR1) on malignant and immunosuppressive cells modulated virus-cancer GPCR-mediated malignant progression and translated sensors of viral molecules into EBV-specific anti-cancer

< GPCR News < GPCRs in Oncology and Immunology The landscape of cancer-rewired GPCR signaling axes Published 2024 Abstract "We explored the dysregulation of G-protein-coupled receptor (GPCR) ligand systems in cancer Multiple GPCRs are differentially regulated together with their upstream partners across cancer subtypes , cancer cell lines , cell-cell communication , drug repurposing , personalized medicine , signaling Meetings, and Webinars Reviews, GPCRs, and more GPCR Binders, Drugs, and more Methods & Updates in GPCR Research

< GPCR News < GPCRs in Oncology and Immunology Pan-cancer functional analysis of somatic mutations in GPCRs) are the most frequently exploited drug target family, moreover they are often found mutated in cancer We explored cancer-related mutation patterns in all GPCR classes combined and individually. Meetings, and Webinars Reviews, GPCRs, and more GPCR Binders, Drugs, and more Methods & Updates in GPCR Research GPCRs in Neuroscience GPCRs in Cardiology, Endocrinology, and Taste GPCRs in Oncology and Immunology

< GPCR News < GPCRs in Oncology and Immunology Systems Pharmacodynamic Model of Combination Gemcitabine and Trabectedin in Pancreatic Cancer Cells. prior study, we reported the synergistic cytotoxic effects of gemcitabine and trabectedin on pancreatic cancer analysis was performed, and a system pharmacodynamics model (SPD) was developed to capture pancreatic cancer Straubinger , William J Jusko Tags Systems Pharmacodynamic , drug combination , gemcitabine , pancreatic cancer

Y1 and Y5 reduces hypoxic breast cancer migration, proliferation, and signaling Published date May 30 This abundance is exploited for cancer imaging, but there is interest in pharmacological inhibition of the NPYRs to interrogate their functional relevance in breast cancer. Tags Breast cancer , GPCR , Hypoxia , NPY , Neuropeptide . Meetings, and Webinars Reviews, GPCRs, and more GPCR Binders, Drugs, and more Methods & Updates in GPCR Research

histamine receptor H1 enhances calcium signaling and cancer cell migration Published date February 1 and is involved in several cancer phenotypes including tumor growth, survival, and metastasis. Here, we show that HRH1 is widely expressed in various cancer cell lines and cancer tissues and that coexpression of CXCR4 and HRH1 is associated with poor prognosis in breast cancer. Meetings, and Webinars Reviews, GPCRs, and more GPCR Binders, Drugs, and more Methods & Updates in GPCR Research

G-protein signaling in cancer Published date April 25, 2023 Abstract " Activation of heterotrimeric GIV/Girdin has emerged as a prototypical non-GPCR activator of G proteins that promotes cancer metastasis blocking noncanonical G-protein signaling in tumor cells and inhibiting proinvasive traits of metastatic cancer Tags G protein , GPCR , cancer , drug discovery . Meetings, and Webinars Reviews, GPCRs, and more GPCR Binders, Drugs, and more Methods & Updates in GPCR Research

< GPCR News < GPCRs in Oncology and Immunology Ultrasensitive dose-response for asbestos cancer risk is expected for damage that accumulates in proportion to dose, as hypothesized for increased risk of cancer relation to genotoxic dose according to the multistage somatic mutation/clonal-expansion theory of cancer Meetings, and Webinars Reviews, GPCRs, and more GPCR Binders, Drugs, and more Methods & Updates in GPCR Research GPCRs in Neuroscience GPCRs in Cardiology, Endocrinology, and Taste GPCRs in Oncology and Immunology

< GPCR News < GPCRs in Oncology and Immunology Itaconate in host inflammation and defense Published date and conjecture a rationale for developing ITA-based therapeutics to treat inflammatory diseases and cancer Authors Dan Ye , Pu Wang , Lei-Lei Chen , Kun-Liang Guan , Yue Xiong Tags IRG1/ACOD1 , cancer , inflammatory Meetings, and Webinars Reviews, GPCRs, and more GPCR Binders, Drugs, and more Methods & Updates in GPCR Research GPCRs in Neuroscience GPCRs in Cardiology, Endocrinology, and Taste GPCRs in Oncology and Immunology

< GPCR News < GPCRs in Oncology and Immunology Lactate receptor GPR81 drives breast cancer growth and Here, we investigate the roles of GPR81 in three-dimensional (3D) and in vivo growth of breast cancer lactate and 3D growth in breast cancer spheroids. Meetings, and Webinars Reviews, GPCRs, and more GPCR Binders, Drugs, and more Methods & Updates in GPCR Research GPCRs in Neuroscience GPCRs in Cardiology, Endocrinology, and Taste GPCRs in Oncology and Immunology

< GPCR News < GPCRs in Oncology and Immunology Deciphering a GPCR-lncRNA-miRNA Nexus: Identification of an Aberrant Therapeutic Target in Ovarian Cancer Published date April 18, 2024 Abstract "Ovarian cancer Previous studies have identified the pivotal role of Lysophosphatidic acid (LPA)-signaling in ovarian cancer xenografts, demonstrating the therapeutic potential of targeting LPAR-UCA1-let-7 axis in ovarian cancer Meetings, and Webinars Reviews, GPCRs, and more GPCR Binders, Drugs, and more Methods & Updates in GPCR Research

< GPCR News < GPCRs in Oncology and Immunology The GPCR-Gαs-PKA signaling axis promotes T cell dysfunction and cancer immunotherapy failure Published date June 12, 2023 Abstract "Immune checkpoint blockade ( ICB) targeting PD-1 and CTLA-4 has revolutionized cancer treatment. However, many cancers do not respond to ICB, prompting the search for additional strategies to achieve we cross-integrated large singe-cell RNA-sequencing datasets from CD8+ T cells covering 19 distinct cancer

< GPCR News < GPCRs in Oncology and Immunology Functional Assessment of Cancer-Linked Mutations in Sensitive Genetic variants in RGS proteins are associated with many diseases, including cancers, although the impact Intolerant and tolerant-control residues that overlap with pathogenic cancer mutations reported in the COSMIC cancer database were selected to define the functional phenotype. Identified intolerant residues with reported cancer-linked mutations RGS14-R173C/H and RGS4-K125Q/E126K

breast cancer cell proliferation by enhancing the ERK pathway Published date January 2, 2023 Abstract Increased VIPR2 mRNA expression and/or VIPR2 gene copy number has been documented in several cancers However, the pathophysiological role of increased VIPR2 in the proliferation of breast cancer cells remains In this study, we found that VIPR2 overexpression in MCF-7 and MDA-MB-231 cells, human breast cancer Increased VIPR2 also exacerbated intraperitoneal proliferation of breast cancer MDA-MB-231 cells in a

< GPCR News < GPCRs in Oncology and Immunology Involvement of Protease-Activated Receptor2 Pleckstrin PAR2 expression in FTs may serve as an early prediction sensor for ovarian cancer. serve as a powerful medicament in STICs and ovarian cancer. Meetings, and Webinars Reviews, GPCRs, and more GPCR Binders, Drugs, and more Methods & Updates in GPCR Research GPCRs in Neuroscience GPCRs in Cardiology, Endocrinology, and Taste GPCRs in Oncology and Immunology

< GPCR News < GPCRs in Oncology and Immunology NPFF stimulates human ovarian cancer cell invasion by Epithelial ovarian cancer (EOC) is a leading cause of death among gynecological malignancies. Fang , Peter C K Leung , Jung-Chien Cheng Tags Invasion , MMP-9 , NPFFR2 , Neuropeptide FF , Ovarian cancer Meetings, and Webinars Reviews, GPCRs, and more GPCR Binders, Drugs, and more Methods & Updates in GPCR Research GPCRs in Neuroscience GPCRs in Cardiology, Endocrinology, and Taste GPCRs in Oncology and Immunology

guanylate kinase (MAGUK) scaffold protein, and protein kinase A anchoring protein (AKAP) 5 in MCF7 breast cancer β1-adrenergic receptor (β1AR) are G protein-coupled receptors (GPCR) that are implicated in breast cancer MCF7 breast cancer cells express GPR30, β1AR, MAGUKs, and AKAP5 in the plasma membrane, and co-immunoprecipitation Stephen Serafin , Tobias Schmidt , Björn Olde , Kathleen M Caron , L M Fredrik Leeb-Lundberg Tags Breast cancer Meetings, and Webinars Reviews, GPCRs, and more GPCR Binders, Drugs, and more Methods & Updates in GPCR Research

< GPCR News < GPCRs in Oncology and Immunology Esophageal and gastric cancer incidence trends in Golestan June 29, 2023 Abstract "Golestan province in the northeast of Iran is part of the Asian esophageal cancer belt and is known as a high-risk area for esophageal (EC) and gastric cancers (GC). on incident cases of EC and GC during 2004 to 2018 were obtained from the Golestan Population-based Cancer Meetings, and Webinars Reviews, GPCRs, and more GPCR Binders, Drugs, and more Methods & Updates in GPCR Research

< GPCR News < GPCRs in Oncology and Immunology Gi/o GPCRs drive the formation of actin-rich tunneling nanotubes in cancer cells via a Gβγ/PKCα/FARP1/Cdc42 axis Published date June 26, 2023 Abstract "The Using a model of human adrenocortical cancer cells, here we established that activation of the GPCR OXER1 Meetings, and Webinars Reviews, GPCRs, and more GPCR Binders, Drugs, and more Methods & Updates in GPCR Research GPCRs in Neuroscience GPCRs in Cardiology, Endocrinology, and Taste GPCRs in Oncology and Immunology

rationales, we studied the capacity of LP2 to inhibit the growth of patient-derived xenografts of colorectal cancer on an untreated tissue array demonstrated that the AT 2 R expression is reduced in human colorectal cancer specificity, safety and stability, warrant further evaluation of LP2's inhibitory potential of colorectal cancer . " Authors P Namsolleck , L de Vries , G N Moll Tags AT(2)R , Agonist , Angiotensin , Cancer , GPCR Meetings, and Webinars Reviews, GPCRs, and more GPCR Binders, Drugs, and more Methods & Updates in GPCR Research